双靶向BCL-XL与MCL-1揭示非小细胞肺癌中一种快速且可利用的凋亡缺陷
Dual targeting of BCL-XL and MCL-1 exposes a rapid and exploitable apoptotic vulnerability in non-small cell lung cancer.
作者
作者单位
- Institute of Pharmacology, University of Bern, Inselspital, INO-F, Bern, Switzerland.
- Institute of Pharmacology, University of Bern, Inselspital, INO-F, Bern, Switzerland. thomas.kaufmann@unibe.ch.
摘要
中文
非小细胞肺癌(NSCLC)在面对致癌信号和治疗性应激时,常常对线粒体凋亡产生抵抗。尽管已有研究提示单个抗凋亡BCL-2家族成员参与NSCLC的存活,但尚不清楚这反映的是单一蛋白的主导依赖性还是协同的促存活网络。这种不确定性因p53突变的高发而加剧,因为p53突变会削弱DNA损伤诱导的凋亡信号通路。本研究中,我们系统性地在多株人NSCLC细胞系中使用选择性BH3模拟物靶向BCL-2、BCL-XL或MCL-1,解析内源性凋亡依赖性。与既往报道一致,单独使用BH3模拟物仅在不同NSCLC模型中对顺铂提供有限且异质的增敏作用。同样,单独抑制BCL-2、BCL-XL或MCL-1仅引起微弱且可变的凋亡反应。引人注目的是,联合靶向BCL-XL与MCL-1足以在大多数NSCLC细胞系中触发快速、协同且不可逆的凋亡,即使在缺乏基因毒性应激的情况下也是如此。细胞死亡的决定发生在数分钟内,其特征为早期线粒体外膜通透化、细胞色素c释放以及强大的效应caspase激活。该凋亡反应严格依赖内源性线粒体机制和BAX/BAK功能,但完全独立于p53状态。在部分模型中观察到的对第一代(WEHI-539)BCL-XL抑制剂的表观耐药,反映的是靶点结合不完全,代偿性存活重塑并不存在。因此,使用新一代BCL-XL抑制剂(A-1331852)或PROTAC介导的BCL-XL降解(DT2216)可完全恢复凋亡。重要的是,血小板保留型BCL-XL靶向策略仍保留与MCL-1抑制的强效协同作用,克服了早期BH3模拟物方法的关键转化限制。综上,这些数据将NSCLC中的凋亡控制重新定义为BCL-XL与MCL-1协同施加的协同性约束,而非离散的、依赖上下文的依赖关系,揭示了一种快速、p53非依赖性的线粒体凋亡缺陷,具有明确的治疗意义。
English
Non-small cell lung cancer (NSCLC) is frequently refractory to mitochondrial apoptosis despite oncogenic and therapeutic stress. Although individual anti-apoptotic BCL-2 family members have been implicated in NSCLC survival, it has remained unclear whether this reflects dominant single-protein dependencies or a cooperative pro-survival network. This uncertainty is exacerbated by the high prevalence of p53 mutations, which compromise DNA damage-induced apoptotic signaling. Here, we systematically dissected intrinsic apoptotic dependencies across a panel of human NSCLC cell lines using selective BH3 mimetics targeting BCL-2, BCL-XL or MCL-1. Consistent with previous reports, BH3 mimetics alone provided only limited and heterogeneous sensitization to cisplatin across NSCLC models. Likewise, single-agent inhibition of BCL-2, BCL-XL or MCL-1 elicited weak and variable apoptotic responses. In striking contrast, combined targeting of BCL-XL and MCL-1 was sufficient to trigger rapid, synergistic and irreversible apoptosis in the majority of NSCLC cell lines, even in the absence of genotoxic stress. Commitment to cell death occurred within minutes and was characterized by early mitochondrial outer membrane permeabilization, cytochrome c release and robust effector caspase activation. This apoptotic response strictly required the intrinsic mitochondrial machinery and BAX/BAK function but was entirely independent of p53 status. Apparent resistance to first-generation (WEHI-539) BCL-XL inhibition in a subset of models reflected incomplete target engagement rather than compensatory survival rewiring. Accordingly, apoptosis was fully restored by next-generation BCL-XL inhibition (A-1331852) or by PROTAC-mediated BCL-XL degradation (DT2216). Importantly, platelet-sparing BCL-XL targeting strategies retained strong synergy with MCL-1 inhibition, addressing a key translational limitation of earlier BH3-mimetic approaches. Together, these data redefine apoptotic control in NSCLC as a cooperative restraint imposed by BCL-XL and MCL-1 rather than discrete, context-dependent dependencies, revealing a rapid, p53-independent mitochondrial apoptotic vulnerability with clear therapeutic implications.
分类与指标
- 研究类型
- 基础研究
- 病种
- 肺癌
- JCR 分区
- Q1
- 影响因子
- 13.6
- 新锐分区
- 1区